Although not yet specifically approved for the treatment of MASLD, GLP-1 RAs exhibit pleiotropic effects that contribute to the improvement of MASLD and its progression to metabolic dysfunction-associated steatohepatitis (MASH) (Table 3). This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.